Aduro, J&J in second cancer pact
Immunotherapy specialist Aduro BioTech Inc. (Berkeley, Calif.) entered into its second licensing agreement with the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE: JNJ). The biotech granted Janssen exclusive, worldwide rights to an unspecified number of candidates to treat lung cancer based on Aduro's live-attenuated double-deleted Listeria monocytogenes (LADD) immunotherapy platform. J&J declined to give details regarding the candidates or status of the programs.
J&J paid Aduro $30 million up front, and is responsible for all development and commercialization. The biotech is eligible to receive up to $817 million in milestones and high single- to double-digit tiered royalties. The deal originated at J&J's California Innovation Center. ...